Corrigendum to: Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer (International Journal of Nanomedicine, (2014) 9, 1, (4035-4041), 10.2147/IJN.S64708);Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 4035-4041

  Hu, Qiang ^a,c   Liang, Bo ^b   Sun, Ying ^d   Guo, Xiao Ling ^b   Bao, Yi Jie ^b   Xie, Dong Hao ^c   Zhou, Ming ^c   Duan, You Rong ^d   Yin, Pei Hao ^b   Peng, Zhi Hai ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Dahua Hospital   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bufalin; Colon cancer; Nanoparticles; Tumor target

Indexed keywords

BUFALIN; NANOPARTICLE; OXALIPLATIN; PLURONIC POLYETHERIMIDE NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BUFADIENOLIDE DERIVATIVE; DRUG CARRIER; POLOXAMER; POLYETHERIMIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL TRANSPORT; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; FEMALE; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; ANIMAL; CHEMISTRY; COLORECTAL TUMOR; DRUG EFFECTS; DRUG SCREENING; HCT 116 CELL LINE; LIVER; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BUFANOLIDES; COLORECTAL NEOPLASMS; DRUG CARRIERS; HCT116 CELLS; HUMANS; LIVER; MALE; MICE; MICE, NUDE; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; POLYMERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928162046     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S138486     Document Type: Erratum

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;16(3):CD005390.
3. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10 Suppl 1:S2.
4. Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 2010;70(16):6401-6406.
5. Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry. 1998;48(1):1-29.
6. Qi F, Li A, Inagaki Y, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011;11(3):342-349.
7. Lu CX, Nan KJ, Lei Y. Agents from amphibians with anticancer properties. Anticancer Drugs. 2008;19(10):931-939.
8. Cui X, Inagaki Y, Xu H, et al. Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells. Biol Pharm Bull. 2010;33(10):1728-1732.
9. Miao Q, Bi LL, Li X, et al. Anticancer effects of Bufalin on human hepatocellular carcinoma HepG2 Cells: roles of apoptosis and autophagy. Int J Mol Sci. 2013;14(1):1370-1382.
10. Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011;51(7):1365-1375.
11. Amano Y, Cho Y, Matsunawa M, Komiyama K, Makishima M. Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J Steroid Biochem Mol Biol. 2009;114(3-5):144-151.
12. Li D, Qu X, Hou K, et al. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 2009;20(1):59-64.
13. Shen S, Zhang Y, Wang Z, Liu R, Gong X. Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. Int J Biol Sci. 2014;10(2):212-224.
14. Tsai SC, Yang JS, Peng SF, et al. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int J Oncol. 2012;41(4):1431-1442.
15. Chen YY, Lu HF, Hsu SC, et al. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways. Environ Toxicol. 2013, Aug 16.
16. Gong LL, Li JX, Zhang HM. Progress on pharmacological action and preparation of Venenum Bufonis. Food Drug. 2007;9(10):51-53.
17. Yin P, Wang Y, Qiu Y, et al. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomedicine. 2012;7:3961-3969.
18. Kim SS, Rait A1, Rubab F, et al. The clinical potential of targeted Nanomedicine: delivering to cancer stem-like cells. Mol Ther. 2014;22(2):278-291.
19. Xia H, Gao X, Gu G, et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials. 2011;32(36):9888-9898.
20. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
21. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-782.
22. Patel NR, Chen ZG, Shin DM. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev. 2013;65(13-14):1748-1762.
23. Venkatasubbu GD, Ramasamy S, Avadhani GS, Palanikumar L, Kumar J. Size-mediated cytotoxicity of nanocrystalline titanium dioxide, pure and zinc-doped hydroxyapatite nanoparticles in human hepatoma cells. J Nanopart Res. 2012;14:819-836.
24. Kasemets K, Ivask A, Dubourguier HC, Kahru A. Toxicity of nanoparticles of ZnO, CuO and TiO2 to yeast Saccharomyces cerevisiae. Toxicol in Vitro. 2009;23(6):1116-1122.
25. Lee BS, Park K, Park S, et al. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. J Control Release. 2010;147(2):253-260.
26. Li F, Wang Y, Liu Z, Lin X, He H, Tang X. Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers. Drug Dev Ind Pharm. 2010;36(5):508-517.